Stay updated on Pembrolizumab & Enobosarm in AR+ Metastatic TNBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Enobosarm in AR+ Metastatic TNBC Clinical Trial page.

Latest updates to the Pembrolizumab & Enobosarm in AR+ Metastatic TNBC Clinical Trial page
- Check7 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference1.0%
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.8%
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check72 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check86 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed descriptions of a clinical trial for pembrolizumab and enobosarm in treating metastatic triple-negative breast cancer, while adding new identifiers and collaborators related to the trial.SummaryDifference53%
Stay in the know with updates to Pembrolizumab & Enobosarm in AR+ Metastatic TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Enobosarm in AR+ Metastatic TNBC Clinical Trial page.